Group items tagged

Most survey-based prevalence estimates of type 1 diabetes among adults have been based on self-reported information about a young age at diagnosis (e.g.,30 years and 40 years) and insulin use within a year of diagnosis. However, this estimation approach misses type 1 diabetes in adults with older age of onset and may misclassify some cases of type 2 diabetes as type 1 if insulin use begins soon after diagnosis. The major goal of this project is to evaluate the validity of survey questions (or algorithms based on them) to distinguish between adults (aged 18 years of age) with type 1 and type 2 diabetes in a representative sample of adult diabetic patients in a diabetes patient registry or database. Using a gold standard, validity will be assessed by examining the sensitivity, specificity, and positive predictive value of algorithms to identify type of diabetes across demographic strata such as age, sex, and race. A secondary goal is to validate definitions of type of diabetes using electronic health records.

The purpose of this Funding Opportunity Announcement (FOA) is to promote the development of an interdisciplinary workforce for conducting bioengineering research to develop innovative technologies for treatment of diabetes including creating integrated long term glucose regulated insulin delivery systems (artificial pancreas), beta cell or islet encapsulation for beta cell replacement therapy, wound healing or prevention for diabetic ulcers, better cellular models of relevant tissues for studying diabetes and its complications and/or beta cell and autoimmunity imaging methods. This FOA will support institutional training programs in diabetes research for pre and postdoctoral level researchers with backgrounds in bioengineering and/or computational sciences.

Pathway supports innovative basic, clinical, translational, epidemiological, behavioral, or health services research relevant to any diabetes type, diabetes-related disease state, or diabetes complication. The Association seeks exceptional candidates from a broad range of disciplines, including medicine, biology, chemistry, computing, physics, mathematics and engineering.

This FOA has two components, A and B. Component A: To support a 5-year multi-center research network of innovative, non-health system-based, natural experiments approaches to alter the diabetogenic characteristics of US communities. Priority areas include population-level approaches to the promotion of healthy eating and active living by evaluating the impact of environmental and policy interventions on population-level risk factors for diabetes. Component B: To fund a Central Coordinating Center (CCC) to provide organizational, logistic and communication support to enhance the efficiency, productivity, and impact of the Natural Experiments research centers that are funded as part of Component A.

This FOA has two components, A and B. Component A: To support a 5-year multi-center research network of innovative, non-health system-based, natural experiments approaches to alter the diabetogenic characteristics of US communities. Priority areas include population-level approaches to the promotion of healthy eating and active living by evaluating the impact of environmental and policy interventions on population-level risk factors for diabetes. Component B: To fund a Central Coordinating Center (CCC) to provide organizational, logistic and communication support to enhance the efficiency, productivity, and impact of the Natural Experiments research centers that are funded as part of Component A.

Type 1 diabetes (T1D) results in part from the autoimmune-mediated dysfunction or destruction of insulin-producing pancreatic beta cells. This funding opportunity is for projects that seek to discover ways to change the course of the disease by directly establishing tolerance. Immune responses could be engineered for tolerance induction through the manipulation of antigens, cells, or cellular microenvironments. Collaborations between T1D experts and investigators from other fields, including (but not limited to) cancer immunology and biomaterials engineering, are especially encouraged.

This Funding Opportunity Announcement (FOA) encourages applications from institutions/organizations proposing original research addressing barriers that limit progress toward effective cell replacement therapies for type 1 diabetes (T1D). The purpose is to support research leading to the development and testing of novel and supportive technologies for the improvement of cell replacement interventions using novel biomaterials and devices for T1D treatment.

One of JDRF's therapeutic goals is to restore beta cell function in type 1 diabetes (T1D) by replacement/transplantation of beta cells/islets. Pancreatic islet transplantation has been efficacious in selected patients in improving metabolic control and quality of life, and in preventing severe hypoglycemia in patients with medically unstable T1D. Despite improvements in cadaveric pancreas procurement, islet isolation, and islet purification, major scientific and technical challenges remain that must be addressed before beta cell replacement could be widely incorporated into the clinical management of established T1D; examples include serious side effects from chronic immunosuppression and the insufficient human islet supply from cadaveric pancreata. JDRF's role is to enable the scientific community to address these challenges with the ultimate goal of developing safe and effective beta cell replacement approaches available to large numbers of individuals with T1D.

One of JDRF's therapeutic goals is to restore beta cell function in type 1 diabetes (T1D) by replacement/transplantation of beta cells/islets. Pancreatic islet transplantation has been efficacious in selected patients in improving metabolic control and quality of life, and in preventing severe hypoglycemia in patients with medically unstable T1D. Despite improvements in cadaveric pancreas procurement, islet isolation, and islet purification, major scientific and technical challenges remain that must be addressed before beta cell replacement could be widely incorporated into the clinical management of established T1D; examples include serious side effects from chronic immunosuppression and the insufficient human islet supply from cadaveric pancreata. JDRF's role is to enable the scientific community to address these challenges with the ultimate goal of developing safe and effective beta cell replacement approaches available to large numbers of individuals with T1D.

In recent years, somatic cells as therapeutic agents have provided new treatment approaches for a number of pathological conditions that were deemed untreatable, or difficult to treat. Several successful cell therapies using T cells have been demonstrated for cancer and autoimmune diseases, while stem cell therapies have given relief for heart disease and stroke. Hundreds of clinical trials are ongoing to examine efficacy of cell therapies for a variety of other diseases including diabetes, Alzheimer's, Parkinson's, and Crohn's disease. Production of therapeutic cells is currently expensive and, therefore, cost prohibitive for the large number of people who might benefit from these treatments. The overarching goal of this Advanced Biomanufacturing of Therapeutic Cells (ABTC) solicitation is to catalyze well-integrated interdisciplinary research to understand, design, and control cell manufacturing systems and processes that will enable reproducible, cost-effective, and high-quality production of cells with predictable performance for the identified therapeutic function.

In recent years, somatic cells as therapeutic agents have provided new treatment approaches for a number of pathological conditions that were deemed untreatable, or difficult to treat. Several successful cell therapies using T cells have been demonstrated for cancer and autoimmune diseases, while stem cell therapies have given relief for heart disease and stroke. Hundreds of clinical trials are ongoing to examine efficacy of cell therapies for a variety of other diseases including diabetes, Alzheimer's, Parkinson's, and Crohn's disease. Production of therapeutic cells is currently expensive and, therefore, cost prohibitive for the large number of people who might benefit from these treatments. The overarching goal of this Advanced Biomanufacturing of Therapeutic Cells (ABTC) solicitation is to catalyze well-integrated interdisciplinary research to understand, design, and control cell manufacturing systems and processes that will enable reproducible, cost-effective, and high-quality production of cells with predictable performance for the identified therapeutic function.

This Funding Opportunity Announcement (FOA) requests applications to explore human pancreatic tissues for the discovery of early biomarkers of T1D pathogenesis, the description of specific signaling or processing pathways that may contribute to the asymptomatic phase of T1D, the development of clinical diagnostic tools for the detection and staging of early T1D in at-risk or recently-diagnosed individuals, and/or the identification of therapeutic targets for the development of preventative or early treatment strategies. Successful applicants will join the Consortium on Beta Cell Death and Survival (CBDS), whose mission is to better define and detect the mechanisms of beta cell stress and destruction central to the development of T1D in humans, with the long-term goal of detecting beta cell destruction and protecting the residual beta cell mass in T1D patients as early as possible in the disease process, and of preventing the progression to autoimmunity. The CBDS is part of a collaborative research framework, the Human Islet Research Network (HIRN, https://hirnetwork.org), whose overall mission is to support innovative and collaborative translational research to understand how human beta cells are lost in T1D, and to find innovative strategies to protect and replace functional beta cell mass in humans. This FOA will only support studies with a primary focus on increasing our understanding of human disease biology (as opposed to rodent or other animal models).

This Funding Opportunity Announcement (FOA) encourages applications from institutions/organizations proposing original research addressing barriers that limit progress toward effective open- and closed-loop glucose control systems. Proposed research should tackle important obstacles at the level of sensing, hormone formulation and delivery, self-management decision support systems, and/or design of automated controllers/algorithms able to manage an integrated platform. This research may contribute to development of affordable and user friendly technologies to improve glucose control in patients with type 1 diabetes.

The purpose of this funding opportunity announcement (FOA) is to stimulate clinical research that applies a social genomics approach to chronic wound risk, presence, progression, and healing. The field of social genomics focuses on how the social environment influences gene expression, and how this gene expression may in turn impact health outcomes. Chronic wounds (e.g., diabetic ulcers, venous or arterial ulcers) are multidimensional and, as such, there is benefit to a holistic approach that goes beyond a focus on the wound (i.e., repairing the skin and underlying tissue) to include an approach that focuses on the person with the wound. A better understanding of social environmental factors (positive and negative) and associated molecular mechanisms is needed to advance therapeutic strategies aimed at reducing chronic wound risk in addition to improving healing outcomes and quality of life.